Immutep Ltd (IMM) - Net Assets

Latest as of June 2025: AU$143.64 Million AUD ≈ $101.63 Million USD

Based on the latest financial reports, Immutep Ltd (IMM) has net assets worth AU$143.64 Million AUD (≈ $101.63 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$156.98 Million ≈ $111.08 Million USD) and total liabilities (AU$13.35 Million ≈ $9.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IMM tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$143.64 Million
% of Total Assets 91.5%
Annual Growth Rate 18.95%
5-Year Change 96.03%
10-Year Change 306.7%
Growth Volatility 169.37

Immutep Ltd - Net Assets Trend (2000–2025)

This chart illustrates how Immutep Ltd's net assets have evolved over time, based on quarterly financial data. See how many days can Immutep Ltd fund operations to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Immutep Ltd (2000–2025)

The table below shows the annual net assets of Immutep Ltd from 2000 to 2025. For live valuation and market cap data, see market cap of Immutep Ltd.

Year Net Assets Change
2025-06-30 AU$143.64 Million
≈ $101.63 Million		 -24.21%
2024-06-30 AU$189.52 Million
≈ $134.10 Million		 +38.87%
2023-06-30 AU$136.47 Million
≈ $96.56 Million		 +45.06%
2022-06-30 AU$94.08 Million
≈ $66.57 Million		 +28.40%
2021-06-30 AU$73.27 Million
≈ $51.84 Million		 +120.04%
2020-06-30 AU$33.30 Million
≈ $23.56 Million		 +36.54%
2019-06-30 AU$24.39 Million
≈ $17.26 Million		 -27.25%
2018-06-30 AU$33.52 Million
≈ $23.72 Million		 +26.34%
2017-06-30 AU$26.53 Million
≈ $18.77 Million		 -24.87%
2016-06-30 AU$35.32 Million
≈ $24.99 Million		 +43.05%
2015-06-30 AU$24.69 Million
≈ $17.47 Million		 +9.28%
2014-06-30 AU$22.59 Million
≈ $15.99 Million		 -22.76%
2013-06-30 AU$29.25 Million
≈ $20.70 Million		 -21.29%
2012-06-30 AU$37.16 Million
≈ $26.29 Million		 -32.56%
2011-06-30 AU$55.10 Million
≈ $38.99 Million		 +228.21%
2010-06-30 AU$16.79 Million
≈ $11.88 Million		 +826.20%
2009-06-30 AU$1.81 Million
≈ $1.28 Million		 -31.17%
2008-06-30 AU$2.63 Million
≈ $1.86 Million		 -35.46%
2007-06-30 AU$4.08 Million
≈ $2.89 Million		 -35.41%
2006-06-30 AU$6.32 Million
≈ $4.47 Million		 -24.29%
2005-06-30 AU$8.34 Million
≈ $5.90 Million		 +62.76%
2004-06-30 AU$5.13 Million
≈ $3.63 Million		 +65.73%
2003-06-30 AU$3.09 Million
≈ $2.19 Million		 -43.35%
2002-06-30 AU$5.46 Million
≈ $3.86 Million		 +31.82%
2001-06-30 AU$4.14 Million
≈ $2.93 Million		 +120.79%
2000-06-30 AU$1.88 Million
≈ $1.33 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Immutep Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 44408132200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$535.07 Million 372.52%
Other Comprehensive Income AU$52.65 Million 36.65%
Other Components AU$1.00 0.00%
Total Equity AU$143.64 Million 100.00%

Immutep Ltd Competitors by Market Cap

The table below lists competitors of Immutep Ltd ranked by their market capitalization.

Company Market Cap
Nebag ag
SW:NBEN
 $55.22 Million
Titania Holding AB Series B
ST:TITA-B
 $55.23 Million
Emami Paper Mills Limited
NSE:EMAMIPAP
 $55.23 Million
Kandi Technologies Group Inc
NASDAQ:KNDI
 $55.23 Million
Cellid Co. Ltd
KQ:299660
 $55.18 Million
GCL Global Holdings Ltd Ordinary Shares
NASDAQ:GCL
 $55.17 Million
Q.S.I Co. LTD
KQ:066310
 $55.16 Million
Phinergy Ltd
TA:PNRG
 $55.16 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Immutep Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 189,521,742 to 143,635,363, a change of -45,886,379 (-24.2%).
  • Net loss of 61,434,165 reduced equity.
  • Other comprehensive income increased equity by 22,583,096.
  • Other factors decreased equity by 7,035,310.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-61.43 Million -42.77%
Other Comprehensive Income AU$22.58 Million +15.72%
Other Changes AU$-7.04 Million -4.9%
Total Change AU$- -24.21%

Book Value vs Market Value Analysis

This analysis compares Immutep Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.54x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.09x to 0.54x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2004-06-30 AU$0.57 AU$0.05 x
2005-06-30 AU$0.52 AU$0.05 x
2006-06-30 AU$0.27 AU$0.05 x
2007-06-30 AU$0.16 AU$0.05 x
2008-06-30 AU$0.01 AU$0.05 x
2009-06-30 AU$0.00 AU$0.05 x
2010-06-30 AU$0.04 AU$0.05 x
2011-06-30 AU$0.13 AU$0.05 x
2012-06-30 AU$0.09 AU$0.05 x
2013-06-30 AU$0.07 AU$0.05 x
2014-06-30 AU$0.05 AU$0.05 x
2015-06-30 AU$0.06 AU$0.05 x
2016-06-30 AU$0.15 AU$0.05 x
2017-06-30 AU$0.13 AU$0.05 x
2018-06-30 AU$0.13 AU$0.05 x
2019-06-30 AU$0.07 AU$0.05 x
2020-06-30 AU$0.08 AU$0.05 x
2021-06-30 AU$0.12 AU$0.05 x
2022-06-30 AU$0.11 AU$0.05 x
2023-06-30 AU$0.16 AU$0.05 x
2024-06-30 AU$0.16 AU$0.05 x
2025-06-30 AU$0.10 AU$0.05 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Immutep Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -42.77%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1218.02%
  • • Asset Turnover: 0.03x
  • • Equity Multiplier: 1.09x
  • Recent ROE (-42.77%) is above the historical average (-67.43%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2004 -98.09% -1411.65% 0.06x 1.14x AU$-5.48 Million
2005 -75.43% -1114.93% 0.06x 1.09x AU$-7.13 Million
2006 -67.34% -2797.82% 0.02x 1.17x AU$-4.89 Million
2007 -76.94% -13647726.09% 0.00x 1.07x AU$-3.55 Million
2008 -71.67% -3254.06% 0.02x 1.07x AU$-2.15 Million
2009 -162.53% -10159.85% 0.01x 1.37x AU$-3.13 Million
2010 -72.43% -2321.57% 0.03x 1.13x AU$-13.84 Million
2011 -38.26% -1977.59% 0.02x 1.05x AU$-26.59 Million
2012 -53.67% -1311.89% 0.04x 1.12x AU$-23.66 Million
2013 -52.06% -496.54% 0.09x 1.12x AU$-18.15 Million
2014 -59.06% -549.84% 0.10x 1.12x AU$-15.60 Million
2015 -130.22% -1715.89% 0.06x 1.25x AU$-34.62 Million
2016 -175.59% -35426.72% 0.00x 1.20x AU$-65.55 Million
2017 -35.30% -227.54% 0.12x 1.32x AU$-12.02 Million
2018 -38.02% -484.55% 0.06x 1.40x AU$-16.10 Million
2019 -66.72% -11640.01% 0.00x 1.66x AU$-18.71 Million
2020 -40.45% -179.90% 0.16x 1.40x AU$-16.80 Million
2021 -40.81% -774.12% 0.05x 1.12x AU$-37.23 Million
2022 -34.24% -18906.51% 0.00x 1.09x AU$-41.62 Million
2023 -29.23% -1138.04% 0.02x 1.08x AU$-53.54 Million
2024 -22.54% -1111.84% 0.02x 1.06x AU$-61.67 Million
2025 -42.77% -1218.02% 0.03x 1.09x AU$-75.80 Million

Industry Comparison

This section compares Immutep Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $5,565,895
  • Average return on equity (ROE) among peers: -157.98%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Immutep Ltd (IMM) AU$143.64 Million -98.09% 0.09x $55.20 Million
Adalta Ltd (1AD) $7.49 Million -79.00% 0.24x $5.41 Million
Algorae Pharmaceuticals Ltd (1AI) $1.80 Million -379.70% 1.37x $14.31 Million
ACRUX Ltd (ACR) $3.28 Million -177.05% 1.74x $4.36 Million
Actinogen Medical Ltd (ACW) $9.37 Million -34.06% 0.09x $78.71 Million
Argenica Therapeutics Ltd (AGN) $8.31 Million -49.24% 0.09x $10.00 Million
Arovella Therapeutics Ltd (ALA) $10.51 Million -87.53% 0.53x $60.73 Million
Anatara Lifesciences Ltd (ANR) $535.97K -364.70% 1.14x $1.92 Million
Alterity Therapeutics Ltd (ATH) $5.61 Million -198.54% 0.38x $108.75 Million
Amplia Therapeutics Ltd (ATX) $4.87 Million -107.62% 0.09x $41.77 Million
Avecho Biotechnology Ltd (AVE) $3.90 Million -102.34% 0.23x $40.65 Million

About Immutep Ltd

AU:IMM Australia Biotechnology
Market Cap
$55.20 Million
AU$78.01 Million AUD
Market Cap Rank
#21574 Global
#761 in Australia
Share Price
AU$0.05
Change (1 day)
+8.16%
52-Week Range
AU$0.04 - AU$0.46
All Time High
AU$0.68
Categories
Companies in Australia Biotechnology
About

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more